secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2026-08-26T22:24:21+00:00
Accession:  0001708599-26-000051
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina enters $25M equity purchase agreement with Roth Principal Investments
----------------------------------------------------------------------------

- Up to $25M of new common stock can be sold to Roth Principal over 36 months at 3-7% discount to VWAP.
- Sales are at Serina's sole discretion; no obligation to sell; proceeds for working capital.
- Exchange cap of 5,077,554 shares (19.99% of outstanding) unless price >= $2.7695 or stockholder approval.
- Roth Principal barred from short sales; Serina pays $100K legal fees plus $7.5K/quarter.
- Registration rights agreement filed; Compass Point engaged as qualified independent underwriter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859926000051/0001708599-26-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859926000051/ser-20260821.htm
  HTML page:      https://secwatch.observer/filing/0001708599-26-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer